18 December 2025 : Clinical Research
Optimizing Nivolumab Efficacy: The Role of Dosing Time in Advanced Non-Small Cell Lung Cancer
Mustafa Ersoy
ABEF 1*
DOI: 10.12659/MSM.950963
Med Sci Monit 2025; 31:e950963
Figure 1 Comparison of treatment response distribution and median progression-free survival (PFS) according to nivolumab administration time(A) Treatment response distribution based on PET-CT assessments according to PERCIST 1.0 criteria, demonstrating significantly higher objective response rates in patients receiving nivolumab before 1 PM compared to those treated after 1 PM (P=0.025). (B) Median progression-free survival (PFS) for patients treated before and after 1 PM, showing a numerical but non-significant trend toward longer PFS in the morning administration group (3.5 vs 3.2 months; P=0.098).